| 000 | 00895 a2200217 4500 | ||
|---|---|---|---|
| 005 | 20250517035026.0 | ||
| 264 | 0 | _c20150813 | |
| 008 | 201508s 0 0 eng d | ||
| 022 | _a1474-5488 | ||
| 024 | 7 |
_a10.1016/S1470-2045(15)70271-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEggermont, A M M | |
| 245 | 0 | 0 |
_aCorrection to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. _h[electronic resource] |
| 260 |
_bThe Lancet. Oncology _cJun 2015 |
||
| 300 |
_ae262 p. _bdigital |
||
| 500 | _aPublication Type: Published Erratum | ||
| 700 | 1 | _aChiarion-Sileni, V | |
| 700 | 1 | _aGrob, J-J | |
| 773 | 0 |
_tThe Lancet. Oncology _gvol. 16 _gno. 6 _gp. e262 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S1470-2045(15)70271-8 _zAvailable from publisher's website |
| 999 |
_c24973340 _d24973340 |
||